Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

13.05USD
23 Apr 2018
Change (% chg)

$-6.65 (-33.76%)
Prev Close
$19.70
Open
$12.80
Day's High
$14.26
Day's Low
$12.41
Volume
2,973,280
Avg. Vol
533,606
52-wk High
$33.99
52-wk Low
$12.41

Chart for

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.OQ Industry Sector
P/E (TTM): 33.22 30.95 32.74
EPS (TTM): 0.99 -- --
ROI: 6.80 14.84 14.38
ROE: 14.90 16.34 16.07

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement.

23 Apr 2018

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT Fresenius said on Monday it would not seek to take over Akorn at more favourable terms, after it terminated the agreement to acquire the U.S. generic drugmaker on Sunday.

23 Apr 2018

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement.

23 Apr 2018

BRIEF-Fresenius says believes that Akorn lawsuit is without foundation

* AKORN, INC. SUES FRESENIUS FOR CONSUMMATION OF MERGER AGREEMENT AFTER ITS TERMINATION BY FRESENIUS

23 Apr 2018

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

23 Apr 2018

UPDATE 1-Jilted Akorn sues Fresenius over deal termination

* Akorn says there was no material adverse effect on business

23 Apr 2018

BRIEF-Akorn Asks Delaware Court To Require Fresenius Kabi To Fulfill Its Obligations Under Merger Agreement

* AKORN ASKS DELAWARE COURT TO REQUIRE FRESENIUS KABI TO FULFILL ITS OBLIGATIONS UNDER MERGER AGREEMENT

23 Apr 2018

Fresenius shares gain after it ditches Akorn takeover

FRANKFURT, April 23 Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business.

23 Apr 2018

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT Fresenius said on Monday it would not seek to take over Akorn at more favorable terms, after it terminated the agreement to acquire the U.S. generic drugmaker on Sunday.

23 Apr 2018

Fresenius says will not renegotiate after cancelling Akorn deal

FRANKFURT, April 23 Fresenius said on Monday it would not seek to take over Akorn at more favourable terms, after it terminated the agreement to acquire the U.S. generic drugmaker on Sunday.

23 Apr 2018

Earnings vs. Estimates